High PLK2 rexpression has been confirmed in osteosarcomas (Shen et al., 2012), and down-regulated PLK2 could be associated with chemotherapy resistance in epithelial ovarian cancer (Syed et al., 2011). The gene discussed is PLK2; the disease is ovarian carcinoma.